



# Indicator Analysis 2022

## Annual report of the certified Gynaecology Cancer Centres

Audit year 2021 / Indicator year 2020

## Table of Contents

Introduction .....	3
General information.....	3
Status of the certification system for Gynaecology Cancer Centres 2021.....	5
Clinical sites taken into account.....	6
Tumour documentation systems in the Centres' clinical sites.....	7
Analysis of basic data.....	8
Analysis of indicators.....	12
Indicator No. 1: Presentation tumour board.....	12
Indicator No. 2: Psycho-oncological counselling (session $\geq$ 25 min).....	13
Indicator No. 3: Counselling social services .....	14
Indicator No. 4: Study participation.....	15
Indicator No. 5: Total case number .....	16
Indicator No. 6a: Primary cases .....	17
Indicator No. 6b: Non-primary cases.....	18
Indicator No. 7: Surgical cases .....	19
Indicator No. 8: Offering of genetic testing (GL ovary QI).....	20
Indicator No. 9: Surgical staging early ovarian cancer (GL ovary QI).....	21
Indicator No. 10: Macroscopic complete resection advanced ovarian cancer (GL ovary QI).....	22
Indicator No. 11: Surgery advanced ovarian cancer (GL ovary QI).....	23
Indicator No. 12: Post-surgical chemotherapy advanced ovarian cancer (GL ovary QI).....	24
Indicator No. 13: First-line chemotherapy of advanced ovarian cancer (GL ovary QI).....	25
Indicator No. 14: Presentation at the tumour board (LL cervix QI).....	26
Indicator No. 15: Details in the pathology report in the case of initial diagnosis and tumour resection (GL cervix QI).....	27
Indicator No. 16: Details in the pathology report in the case of lymphonodectomy (GL cervix QI).....	28
Indicator No. 17: Cytological/histological lymph node staging (GL cervix QI).....	29
Indicator No. 18: Brachytherapy as a component of primary radio(chemo) therapy.....	30
Indicator No. 19: Details in pathology report in the case of initial diagnosis and tumour resection (GL vulva QI).....	31
Indicator No. 20: Details in pathology report in the case of lymphonodectomy (GL vulva QI).....	32
Indicator No. 21: Conduct inguino femoral staging (GL vulva QI).....	33
Indicator No. 22: Sentinel lymph nodes biopsy (GL vulva QI) .....	34
Indicator No. 23: Systematic lymphadenectomy (LNE) for type-I-endometrial carcinoma (GL endo. QI) .....	35
Indicator No. 24: Adjuvant chemotherapy for type-I-endometrial carcinoma (GL endo QI).....	36
Impressum .....	37

## General information

Indicator No. 1:	Presentation tumour board
Indicator No. 2:	Psycho-oncological counselling (session ≥ 25 min)
Indicator No. 3:	Counselling social services
Indicator No. 4:	Study participation
Indicator No. 5:	Total case number with a genital malignoma
Indicator No. 6:	Primary cases with a genital malignoma
Indicator No. 7:	Surgical cases with a genital malignoma
Indicator No. 8:	Surgical staging early ovary carcinoma (GL ovary QI 1)
Indicator No. 9:	Macroscopic complete resection advanced ovary carcinoma (GL ovary QI 3)
Indicator No. 10:	Surgery advanced ovary carcinoma (GL ovary QI 4)
Indicator No. 11:	Post-surgical chemotherapy advanced ovary carcinoma (GL ovary QI 5)
Indicator No. 12:	No adjuvant chemotherapy of early ovary carcinoma (LL ovary QI 6)
Indicator No. 13:	Platin-containing chemotherapy early ovary carcinoma (GL ovary QI 7)
Indicator No. 14:	First-line chemotherapy of advanced ovary carcinoma (GL ovary QI 8)


### Quality indicators of the guidelines (GL QI):

In the table of contents and in the respective headings, the indicators which correspond to the quality indicators of the evidence-based guidelines are specifically identified. These quality indicators are based on the strong recommendations of the guidelines and were derived from the guideline groups in the context of the German Guideline Programme in Oncology (GGPO). Further information: [www.leitlinienprogramm-onkologie.de](http://www.leitlinienprogramm-onkologie.de)\*

	Definition of indicator	All clinical sites 2014	
		Median	Range
Numerator	All surgically treated primary cases presented in the tumour conference	151*	46 - 801
Population	Surgically treated primary cases (for definition of a primary case see 5.2.1)	152*	46 - 806
Rate	Target ≥ 95%	100%	93.75% - 100%

### Basic data indicator:

The definition of numerator, denominator and target are taken from the data sheet. The specification of the median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort. Under range, the range of values for numerator, denominator and rate of all centres is given. The column Total patients shows the sum of all patients treated according to the indicator as well as the corresponding rate.




### Diagram:

The x-axis indicates the number of centres, the y-axis gives the values in percent or number (e.g, primary cases). The target value is depicted as a horizontal orange line. The median, which is also depicted as an orange horizontal line, divides the entire group into two equal halves.


\*For further information on the methodological approach see „Development of guideline-based quality indicators“ ([https://www.leitlinienprogramm-onkologie.de/fileadmin/user\\_upload/Downloads/Methodik/QIEP\\_OL\\_Version2\\_english.pdf](https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Methodik/QIEP_OL_Version2_english.pdf))

## General information



### Cohort development:

The cohort development in the years 2016, 2017, 2018, 2019 and 2020 is graphically represented with box plots.



### Box plot:

A box plot consists of a box with median, whiskers and outliers, 50 percent of the centres are within the box. The median divides the entire available cohort into two halves with an equal number of centres. The whiskers and the box encompass a 90th percentile area/range. The extreme values are depicted here as dots.

Maximalwert = Maximum value  
Antenne = Antenna  
Minimalwert = Minimum value

## Status of the certification system for Gynaecology Cancer Centres 2021

	31.12.2021	31.12.2020	31.12.2019	31.12.2018	31.12.2017	31.12.2016
Ongoing procedures	7	8	12	4	10	6
Certified Centres	182	164	155	143	134	133
Certified clinical sites	183	165	156	145	136	135
Gynaecology Cancer Centres with 1 clinical site	181	163	154	141	132	131
2 clinical sites	1	1	1	2	2	2
3 clinical sites	0	0	0	0	0	0
4 clinical sites	0	0	0	0	0	0

**Clinical sites taken into account**

	31.12.2021	31.12.2020	31.12.2019	31.12.2018	31.12.2017	31.12.2016
Clinical sites included in the Annual Report	169	162	149	139	128	125
equivalent to	92,3%	98,8%	95,5%	95,9%	94,1%	92,6%
Primary cases total*	15.254	14.986	13.762	12.937	12.087	11.587
Primary cases per clinical site (mean)*	90	92	92	93	94	93
Primary cases per clinical site (median)*	75	78	78	77	76	79


\*The figures are based on the clinical sites listed in the Annual Report.

This annual report looks at the gynaecological cancer centres certified in the certification system of the German Cancer Society. The basis for the diagrams in the annual report is the data sheet.

The annual report includes 169 of the 183 certified centre locations. Excluded are 12 sites that were certified for the first time in 2021 (data mapping of complete calendar year not mandatory for first-time certifications) and 2 sites where the certificate was reinstated in 2021. A total of 16,061 primary cases with genital malignancy were treated at all 183 sites. A current overview of all certified sites is shown on [www.oncomap.de](http://www.oncomap.de).

The indicators published here refer to the indicator year 2020. They represent the assessment basis for the audits carried out in 2021.

## Tumour documentation systems in the Centres' clinical sites




Andere = other  
 Tumorzentrum = Tumour centre  
 Tumorregister = Tumour registry  
 Entwicklung = Development

Legend:	
Other	System used in ≤ 3 clinical sites

The details on the tumour documentation system were taken from the data sheet (spreadsheet basic data). It is not possible to use more than one system. In many cases support is provided by the cancer registries or there may be a direct connection to the cancer registry via a specific tumour documentation system.

## Basic data – total case number (primary and non-primary cases)



	Total case number	Primary cases	Non-primary cases
Ovarian cancer	6.923 (32,66%)	4.250 (27,86%)	2.673 (45,00%)
Borderline ovary	1.011 (4,77%)	933 (6,12%)	78 (1,31%)
Cervical carcinoma	3.522 (16,62%)	2.664 (17,46%)	858 (14,44%)
Endometrial carcinoma	5.876 (27,72%)	4.753 (31,16%)	1.123 (18,91%)
Vulvar cancer	2.370 (11,18%)	1.643 (10,77%)	727 (12,24%)
Vaginal carcinoma	309 (1,46%)	205 (1,34%)	104 (1,75%)
Others*	1.183 (5,58%)	806 (5,28%)	377 (6,35%)
<b>Total case number</b>	<b>21.194 (100%)</b>	<b>15.254 (100%)</b>	<b>5.940 (100%)</b>


	Incidence <sup>1</sup> Germany	Primary cases 2019 <sup>2</sup>	Share 2020	Primary Cases Germany 2018	Share 2018
Ovarian cancer	7.462	4.097	54,91%	3.798	50,90%
Borderline ovary	-	876	-	884	-
Cervical carcinoma	4.322	2.587	59,86%	2.479	57,36%
Endometrial carcinoma	10.861	4.633	42,66%	4.487	41,31%
Vulvar cancer	3.272	1.647	50,34%	1.579	48,26%
Vaginal carcinoma	473	194	41,02%	202	42,71%
Others*	913	784	85,87%	671	73,49%

\* Others (for instance sarcomas, chorion carcinomas, etc.)

<sup>1</sup> Centre for cancer register data in the Robert Koch-Institute, incidence 2018.

<sup>2</sup> including primary cases not yet part of the annual report (Germany only)  
database query [www.krebsdaten.de/abfrage](http://www.krebsdaten.de/abfrage) 04.07.2022

## Basic data – primary and non-primary cases



<sup>1</sup> Pat. with recurrence/ sec. distant metastasis


	Primary cases		
		operated	not operated
	Total	absolute (in %)	absolute (in %)
Ovarian cancer	4.250 (100%)	3.685 (86,71%)	565 (13,29%)
Borderline ovary	933 (100%)	926 (99,25%)	7 (0,75%)
Cervical carcinoma	2.664 (100%)	2.031 (76,24%)	633 (23,76%)
Endometrial carcinoma	4.753 (100%)	4.381 (92,17%)	372 (7,83%)
Vulvar cancer	1.643 (100%)	1.450 (88,25%)	193 (11,75%)
Vaginal carcinoma	205 (100%)	110 (53,66%)	95 (46,34%)
Others*	806 (100%)	706 (87,59%)	100 (12,41%)
<b>Total</b>	<b>15.254</b>	<b>13.289</b>	<b>1.965</b>

	Non-primary cases		
		operated	not operated
	Total	absolute (in %)	absolute (in %)
Ovarian cancer	2.673 (100%)	597 (22,33%)	2.076 (77,67%)
Borderline ovary	78 (100%)	67 (85,90%)	11 (14,10%)
Cervical carcinoma	858 (100%)	245 (28,55%)	613 (71,45%)
Endometrial carcinoma	1.123 (100%)	337 (30,01%)	786 (69,99%)
Vulvar cancer	727 (100%)	459 (63,14%)	268 (36,86%)
Vaginal carcinoma	104 (100%)	47 (45,19%)	57 (54,81%)
Others*	377 (100%)	156 (41,38%)	221 (58,62%)
<b>Total</b>	<b>5.940</b>	<b>1.908</b>	<b>4.032</b>


\* Others (for instance sarcomas, chorion carcinomas, etc.)

## Surgical cases with a genital malignoma

### Surgical primary cases



### Surgical non-primary cases (pat. with recurrence / sec. distant metastasis)




<sup>1</sup> (Pat. with recurrence/ sec. distant metastasis)

	2016	2017	2018	2019	2020
Max	310,00	342,00	328,00	371,00	395,00
95. percentile	157,30	149,00	171,60	151,95	155,20
75. percentile	104,25	97,00	93,00	92,00	92,00
Median	68,00	71,00	70,00	67,00	66,00
25. percentile	58,00	57,00	56,00	54,25	54,00
5. percentile	44,35	44,00	41,40	40,00	40,00
Min	40,00	36,00	30,00	33,00	29,00


	2016	2017	2018	2019	2020
Max	69,00	92,00	89,00	92,00	76,00
95. percentile	30,00	30,20	32,60	28,95	32,60
75. percentile	17,00	13,00	13,00	12,00	12,00
Median	9,00	9,00	8,00	8,00	8,00
25. percentile	5,00	5,00	5,00	5,00	5,00
5. percentile	1,35	2,00	2,00	2,00	2,00
Min	0,00	0,00	1,00	0,00	0,00

## Basic data - Primary cases ovary and cervix


**Ovary cancer: Primary cases operated + not operated**



**Cervix carcinoma: Primary cases operated + not operated**




# 1. Presentation tumour board



	Indicator definition	All clinical sites 2020		
		Median	Range	Patients Total
Numerator	Patients who were presented at the tumour board	97*	49 - 648	20598
Denominator	Total case number (= indicator 5)	99*	58 - 744	21194
Rate	Target value ≥ 80%	98,80%	81,67% - 100%	97,19%**

Sollvorgabe = target value



	2016	2017	2018	2019	2020
Max	100%	100%	100%	100%	100%
95 <sup>th</sup> percentile	100%	100%	100%	100%	100%
75 <sup>th</sup> percentile	99,64%	100%	100%	100%	100%
Median	97,98%	97,93%	98,17%	98,73%	98,80%
25 <sup>th</sup> percentile	96,09%	94,87%	95,35%	96,44%	96,00%
5 <sup>th</sup> percentile	87,91%	85,79%	87,36%	86,64%	89,89%
Min	81,07%	80,00%	72,04%	80,38%	81,67%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
169	100,00%	169	100,00%


**Comments:**

As in the previous year, all centres achieved the target of at least 80% in 2020. 58 centres (previous year: 60) even succeeded in achieving a 100% presentation rate. A further improvement is particularly evident in the lower percentage ranges.

\*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators  
 \*\* Percentage of the total number of patients treated in centres according to the indicator.




## 2. Psycho-oncological counselling (session ≥ 25 min)



169 Clinical sites

Begründungspflicht = mandatory statement of reasons

	Indicator definition	All clinical sites 2020		
		Median	Range	Patients Total
Numerator	Patients (= cases, definition 1.2.1), who received, in an outpatient or inpatient setting, psycho-oncological counselling (session ≥ 25 min.)	56*	12 - 445	10950
Denominator	Total case number (= indicator 5)	99*	58 - 744	21194
Rate	Mandatory statement of reasons*** < 15% and >95%	52,94%	12,36% - 94,32%	51,67%**



	2016	2017	2018	2019	2020
Max	100%	100%	95,00%	94,74%	94,32%
95 <sup>th</sup> percentile	87,27%	86,35%	83,98%	86,35%	84,98%
75 <sup>th</sup> percentile	71,46%	70,18%	69,51%	69,36%	66,32%
Median	51,72%	50,63%	51,81%	51,49%	52,94%
25 <sup>th</sup> percentile	36,05%	36,16%	35,05%	35,29%	34,58%
5 <sup>th</sup> percentile	17,69%	20,77%	19,05%	20,27%	19,20%
Min	10,11%	12,66%	10,42%	8,15%	12,36%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
169	100,00%	168	99,41%

### Comments:

The psycho-oncology care rate has continued to increase slightly at the median and overall. This is remarkable in view of the pandemic-related restrictions. 1 centre (previous year: 2) required justification with a rate of less than 15%. It explained in the audit that it had reduced screening and consultation activities due to corona-related staff shifts and contact restrictions. The auditors issued a remark, as the rates were already low before.


\*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators

\*\* Percentage of the total number of patients treated in centres according to the indicator.

\*\*\* If value is outside the plausibility corridor, centres have to give an explanation.




### 3. Counselling social services



Begründungspflicht = mandatory statement of reasons

169 Clinical sites

	Indicator definition	All clinical sites 2020		
		Median	Range	Patients Total
Numerator	Patients (= cases, definition 1.2.2), who received counselling by the social services in an inpatient or outpatient setting	65*	17 - 358	12858
Denominator	Total case number (= indicator 5)	99*	58 - 744	21194
Rate	Mandatory statement of reasons*** < 30%	63,16%	8,50% - 90,96%	60,67%**



	2016	2017	2018	2019	2020
Max	100%	96,77%	96,04%	93,83%	90,96%
95 <sup>th</sup> percentile	88,58%	89,23%	88,51%	87,22%	87,46%
75 <sup>th</sup> percentile	75,55%	76,92%	75,53%	76,22%	74,70%
Median	66,00%	66,83%	65,43%	65,91%	63,16%
25 <sup>th</sup> percentile	52,36%	54,06%	51,61%	52,21%	52,09%
5 <sup>th</sup> percentile	29,14%	32,00%	31,69%	33,13%	36,20%
Min	11,56%	14,05%	12,62%	11,96%	8,50%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
169	100,00%	166	98,22%

**Comments:**  
 In contrast to psycho-oncology, the counselling rate at the social service has slightly decreased. This phenomenon can also be observed in other tumour entities. Nevertheless, 1 centre less than in the previous year fell below the threshold of mandatory statement. However, all 3 centres were located in countries outside of Germany, where other benefit entitlements or responsibilities apply with regard to social counselling.


\*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators

\*\* Percentage of the total number of patients treated in centres according to the indicator.


\*\*\* If value is outside the plausibility corridor, centres have to give an explanation.



## 4. Study participation



	Indicator definition	All clinical sites 2020		
		Median	Range	Patients Total
Numerator	Patients of the Gynaecology Cancer Centre included in a study with an ethical vote	8*	0 - 428	3253
Denominator	Primary cases (= indicator 6)	75*	41 - 433	15254
Rate	Target value ≥ 5%	10,26%	0,00% - 190,22%	21,33%**



	2016	2017	2018	2019	2020
Max	94,76%	77,03%	131,05%	300,00%	190,22%
95 <sup>th</sup> percentile	53,69%	45,66%	59,97%	54,16%	51,00%
75 <sup>th</sup> percentile	16,14%	18,32%	16,44%	17,54%	18,39%
Median	8,59%	9,21%	7,69%	8,60%	10,26%
25 <sup>th</sup> percentile	4,34%	5,04%	5,00%	5,29%	6,25%
5 <sup>th</sup> percentile	0,00%	0,00%	0,00%	1,39%	0,49%
Min	0,00%	0,00%	0,00%	0,00%	0,00%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
169	100,00%	140	82,84%


**Comments:**

The dispersion of the study rates has fallen significantly - probably due to the Corona pandemic - but the median has risen significantly. This is remarkable in the overall picture. 29 centres (previous year: 37) failed to meet the target and justified this, among other things, with few suitable studies (11 mentions), rejection by the patients<sup>1</sup>(8x) and negative screening with regard to the inclusion criteria (5x). In the audits, 16 references and 3 deviations were made.

\*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators  
 \*\* Percentage of the total number of patients treated in centres according to the indicator.




## 5. Total case number



	Indicator definition	All clinical sites 2020		
		Median	Range	Patients Total
Number	Total cases (Def. 1.2.1)	99	58 - 744	21194
	Target value ≥ 75			

Sollvorgabe = target value




	2016	2017	2018	2019	2020
Max	571,00	654,00	649,00	722,00	744,00
95 <sup>th</sup> percentile	253,65	262,00	255,80	250,70	250,00
75 <sup>th</sup> percentile	147,00	145,50	133,00	141,75	135,00
Median	106,50	101,00	101,00	97,00	99,00
25 <sup>th</sup> percentile	89,00	86,00	86,00	85,00	84,00
5 <sup>th</sup> percentile	76,35	75,90	76,40	77,05	75,00
Min	67,00	63,00	65,00	68,00	58,00

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
169	100,00%	162	95,86%

### Comments:


Despite 7 additional sites, the total number of cases remained almost unchanged with an increase of 1.1%. The centres that have been certified since at least 2018 recorded a decrease in the total number of cases in the first Covid year (- 386 cases). With 7 centres, 6 more missed the target than in the previous year. With the exception of one centre, all referred to reduced capacities due to corona or patients' reluctance to stay in hospital. The centres all expected an increase in the number of cases for the following year. 6 of the 7 centres were in surveillance audit, with the 10% rule suspended for 2020. The remaining centre took advantage of the Covid 19 exemption rule (3-year average total caseload achieved).

## 6a. Primary cases



	Indicator definition	All clinical sites 2020		
		Median	Range	Patients Total
Number	Primary cases (Def. 1.2.1)	75	41 - 433	15254
	Target value ≥ 50			

Sollvorgabe = target value




	2016	2017	2018	2019	2020
Max	332,00	364,00	352,00	413,00	433,00
95 <sup>th</sup> percentile	172,85	164,20	184,20	172,95	172,20
75 <sup>th</sup> percentile	107,50	105,00	103,00	103,50	101,00
Median	75,50	77,00	78,00	78,00	75,00
25 <sup>th</sup> percentile	65,00	65,00	66,00	63,00	64,00
5 <sup>th</sup> percentile	52,35	52,90	52,80	52,00	51,00
Min	45,00	43,00	42,00	48,00	41,00

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
169	100,00%	165	97,63%


### Comments:

The median number of primary cases has decreased. The total number of primary cases has only slightly decreased in the centres that have been certified since at least 2019 (- 237 cases in 162 locations). 4 centres (previous year: 1) failed to meet the target of at least 50. These were also conspicuous in indicator 5 (total number of cases). The reasons therefore also refer almost exclusively to the Corona pandemic.

## 6. Non primary cases



	Indicator definition	All clinical sites 2020		
		Median	Range	Patients Total
Number	Non primary cases	25	7 - 320	5940
	No target value			




	2016	2017	2018	2019	2020
Max	239,00	290,00	297,00	309,00	320,00
95 <sup>th</sup> percentile	88,15	119,90	104,20	97,90	84,60
75 <sup>th</sup> percentile	43,00	40,00	39,00	39,00	37,00
Median	30,00	26,00	27,00	26,00	25,00
25 <sup>th</sup> percentile	20,00	18,50	19,00	20,00	20,00
5 <sup>th</sup> percentile	12,35	11,00	11,00	12,00	11,00
Min	6,00	8,00	6,00	5,00	7,00

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
169	100,00%	-----	-----

**Comments:**


The number of recurrences and secondary distant metastases was presented as a separate indicator for the first time in the indicator year 2020, although it had already been collected in the basic data for some time. On average, 25 patients in this group were treated per centre, a slight decrease compared to the previous year.

## 7. Surgical cases



	Indicator definition	All clinical sites 2020		
		Median	Range	Patients Total
Number	Surgical cases	73	33 - 471	15197
	Target value ≥ 40			

Sollvorgabe = target value




	2016	2017	2018	2019	2020
Max	355,00	412,00	402,00	446,00	471,00
95 <sup>th</sup> percentile	186,55	178,10	190,80	183,55	176,00
75 <sup>th</sup> percentile	115,25	113,50	109,00	106,00	105,00
Median	80,50	77,00	77,00	73,50	73,00
25 <sup>th</sup> percentile	66,00	64,00	64,00	60,25	60,00
5 <sup>th</sup> percentile	51,00	48,90	46,40	46,05	46,00
Min	44,00	40,00	36,00	40,00	33,00

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
169	100,00%	167	98,82%


**Comments:**

The number of surgeries performed in the centres that have been certified since at least 2019 decreased only slightly in the first Corona year (-255 operations in 162 centres). After all centres had met the targets in the previous year, 2 centres failed to do so in 2020. These centres also failed to meet the target for indicators 5 and 6a and thus referred to the same reasons (Corona pandemic).

## 8. Offering of genetic testing (GL ovary QI)



	Indicator definition	All clinical sites 2020		
		Median	Range	Patients Total
Numerator	Primary cases of the denominator with offer genetic testing	14*	0 - 160	3057
Denominator	Primary cases ovarian carcinoma	19*	3 - 232	4250
Rate	No target value	73,33%	0,00% - 100%	71,93%**



	2016	2017	2018	2019	2020
● Max	----	----	----	100%	100%
95 <sup>th</sup> percentile	----	----	----	100%	100%
75 <sup>th</sup> percentile	----	----	----	82,86%	89,19%
Median	----	----	----	61,11%	73,33%
25 <sup>th</sup> percentile	----	----	----	38,46%	55,56%
5 <sup>th</sup> percentile	----	----	----	7,69%	15,90%
● Min	----	----	----	0,00%	0,00%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
169	100,00%	----	----

### Comments:


There is no target for this QI of the guideline so far, so that no statements can be made about the reasons for the different high rates. In the first year of the mandatory documentation, however, the median has already increased significantly to 73%.

\*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators

\*\* Percentage of the total number of patients treated in centres according to the indicator.


\*\*\* If value is outside the plausibility corridor, centres have to give an explanation.

## 9. Surgical staging early ovarian cancer (GL ovary QI)



Begründungspflicht = mandatory statement of reasons

	Indicator definition	All clinical sites 2020		
		Median	Range	Patients Total
Numerator	Surgical primary cases with surgical staging (Def. see Data Sheet)	5*	1 - 39	995
Denominator	Surgical primary cases with an ovarian cancer FIGO I-III A	6*	1 - 51	1297
Rate	Mandatory statement of reasons*** < 20%	85,71%	16,67% - 100%	76,72%**



	2016	2017	2018	2019	2020
● Max	100%	100%	100%	100%	100%
95 <sup>th</sup> percentile	100%	100%	100%	100%	100%
75 <sup>th</sup> percentile	100%	100%	100%	100%	100%
Median	85,71%	83,33%	86,61%	84,62%	85,71%
25 <sup>th</sup> percentile	69,69%	66,67%	69,17%	63,64%	60,00%
5 <sup>th</sup> percentile	27,92%	40,00%	34,79%	33,33%	30,59%
● Min	0,00%	25,00%	0,00%	0,00%	16,67%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
167	98,82%	166	99,40%

### Comments:


With a slightly increased median, only 1 centre (previous year: 2) fell below the 20% quota, which goes hand in hand with an obligation to give reasons. In 5 out of 6 patients, the centre concerned referred to individual case decisions (e.g. the patient's wish for fertility-preserving surgery). This could be plausibilised in the audits.

\*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators

\*\* Percentage of the total number of patients treated in centres according to the indicator.


\*\*\* If value is outside the plausibility corridor, centres have to give an explanation.

## 10. Macroscopic complete resection of advanced ovarian cancer (GL ovary QI)



Sollvorgabe = target value

	Indicator definition	All clinical sites 2020		
		Median	Range	Patients Total
Numerator	Surgical primary cases with macroscopic complete resection	8*	0 - 134	1747
Denominator	Surgical primary cases ovarian cancer FIGO IIB-IV	10,5*	2 - 174	2325
Rate	Target value $\geq 30\%$	75,00%	0,00% - 100%	75,14%**



	2016	2017	2018	2019	2020
● Max	100%	100%	100%	100%	100%
95 <sup>th</sup> percentile	100%	100%	100%	100%	100%
75 <sup>th</sup> percentile	84,16%	82,74%	84,62%	85,71%	86,67%
Median	69,66%	70,59%	70,00%	73,33%	75,00%
25 <sup>th</sup> percentile	54,49%	57,52%	56,25%	62,50%	61,16%
5 <sup>th</sup> percentile	33,33%	39,87%	38,50%	40,00%	37,63%
● Min	15,38%	19,05%	0,00%	25,00%	0,00%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
168	99,41%	166	98,81%

### Comments:


Over the years, a positive development of the median can be seen. As in the previous year, 2 centres performed a macroscopically complete resection in less than 30% of operative primary cases with ovarian cancer FIGO IIB-IV. These were 2 different centres from the previous year. These had only 2 and 5 patients respectively in the denominator and referred, among other things, to large intra-abdominal tumours with diffuse adhesions, comorbidities and a peritoneal cytology already performed preoperatively, which could no longer be assigned to the resection (and thus made it appear incomplete).

\*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators

\*\* Percentage of the total number of patients treated in centres according to the indicator.

\*\*\* If value is outside the plausibility corridor, centres have to give an explanation.


# 11. Surgery advanced ovarian cancer (GL ovary QI)



Begründungspflicht = mandatory statement of reasons

168 Clinical sites

	Indicator definition	All clinical sites 2020		
		Median	Range	Patients Total
Numerator	Surgical primary cases ovarian cancer whose definitive surgical therapy was performed by a gynaeco-oncologist	10*	2 - 174	2206
Denominator	Surgical primary cases ovarian cancer FIGO IIB-IV after completion of surgical therapy	10,5*	2 - 174	2325
Rate	Mandatory statement of reasons*** < 50%	100%	44,44% - 100%	94,88%**



	2016	2017	2018	2019	2020
Max	100%	100%	100%	100%	100%
95 <sup>th</sup> percentile	100%	100%	100%	100%	100%
75 <sup>th</sup> percentile	100%	100%	100%	100%	100%
Median	100%	100%	100%	100%	100%
25 <sup>th</sup> percentile	81,82%	83,33%	87,50%	89,17%	92,15%
5 <sup>th</sup> percentile	66,67%	59,93%	60,00%	66,82%	64,70%
Min	40,00%	25,00%	50,00%	54,55%	44,44%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
168	99,41%	167	99,40%

**Comments:**

While in the previous year at least 50% of advanced ovarian carcinomas were operated by gynaecological oncologists in all centres, one centre fell just short of this mark in 2020. The centre explained that 5 out of 9 operations were performed by a senior physician who had not yet passed the gynaecological oncology examination, but who already fulfilled all the necessary requirements.


\*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators

\*\* Percentage of the total number of patients treated in centres according to the indicator.

\*\*\* If value is outside the plausibility corridor, centres have to give an explanation.




## 12. Post-surgical chemotherapy advanced ovarian cancer (GL ovary QI)



168 Clinical sites

Begründungspflicht = mandatory statement of reasons

	Indicator definition	All clinical sites 2020		
		Median	Range	Patients Total
Numerator	Surgical primary cases ovarian cancer with post-operative chemotherapy	8*	1 - 171	1769
Denominator	Surgical primary cases ovarian cancer FIGO IIB-IV and chemotherapy	9*	1 - 174	2116
Rate	Mandatory statement of reasons*** < 30%	91,29%	20,00% - 100%	83,60%**



	2016	2017	2018	2019	2020
● Max	100%	100%	100%	100%	100%
95 <sup>th</sup> percentile	100%	100%	100%	100%	100%
75 <sup>th</sup> percentile	100%	100%	100%	100%	100%
Median	90,91%	90,00%	94,28%	88,89%	91,29%
25 <sup>th</sup> percentile	76,74%	80,00%	80,00%	77,14%	76,81%
5 <sup>th</sup> percentile	51,17%	54,10%	55,80%	50,00%	53,85%
● Min	40,00%	33,33%	30,77%	40,91%	20,00%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
168	99,41%	167	99,40%

### Comments:

After fully meeting this indicator in the previous year, 1 centre provided chemotherapy postoperatively in less than 30% of cases for advanced ovarian cancer. The centre had only 5 patients in the denominator. Among other things, it referred to one patient who died postoperatively. The QI has been suspended since audit year 2022 because an update of the underlying guideline recommendation is pending.


\*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators

\*\* Percentage of the total number of patients treated in centres according to the indicator.

\*\*\* If value is outside the plausibility corridor, centres have to give an explanation.




### 13. First-line chemotherapy of advanced ovarian cancer (GL ovary QI)



Begründungspflicht = mandatory statement of reasons

169 Clinical sites

	Indicator definition	All clinical sites 2020		
		Median	Range	Patients Total
Numerator	Primary cases ovarian cancer with 6 cycles first-line chemotherapy carboplatin AUC 5 and paclitaxel 175 mg/m2	9*	0 - 182	1887
Denominator	Primary cases ovarian cancer FIGO IIB-IV	15*	2 - 199	3314
Rate	Mandatory statement of reasons*** < 20%	53,85%	0,00% - 100%	56,94%**



	2016	2017	2018	2019	2020
● Max	100%	100%	100%	100%	100%
95 <sup>th</sup> percentile	94,42%	91,09%	94,62%	92,86%	91,67%
75 <sup>th</sup> percentile	77,60%	77,78%	80,00%	71,43%	73,33%
Median	63,97%	64,71%	60,87%	57,14%	53,85%
25 <sup>th</sup> percentile	42,86%	50,00%	47,22%	42,98%	40,38%
5 <sup>th</sup> percentile	21,32%	24,85%	24,40%	23,08%	22,12%
● Min	0,00%	0,00%	0,00%	10,00%	0,00%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
169	100,00%	165	97,63%

**Comments:**

As in the previous year, 4 centres were below a rate of 20% for first-line chemotherapy for advanced ovarian cancer. 2 of them were already below this value in the previous year. The reasons given by the centres were quite differentiated and varied. All referred to patients who had refused chemotherapy, 3 each to alternative regimens due to age/comorbidity and patients who had already died before starting therapy. Since the audit year 2022, the QI has been adapted so that only substances and no longer the dosages are documented..


\*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators

\*\* Percentage of the total number of patients treated in centres according to the indicator.

\*\*\* If value is outside the plausibility corridor, centres have to give an explanation.




## 14. Presentation at the tumour board (GL cervix QI)



Sollvorgabe = target value

	Indicator definition	All clinical sites 2020		
		Median	Range	Patients Total
Numerator	Patients of the denominator who were presented at the tumour board	16*	3 - 89	3426
Denominator	Primary cases and "non-primary cases" with a cervical carcinoma	16*	3 - 89	3522
Rate	Target value $\geq 80\%$	100%	80,00% - 100%	97,27%**



	2016	2017	2018	2019	2020
● Max	100%	100%	100%	100%	100%
95 <sup>th</sup> percentile	100%	100%	100%	100%	100%
75 <sup>th</sup> percentile	100%	100%	100%	100%	100%
Median	100%	100%	100%	100%	100%
25 <sup>th</sup> percentile	93,75%	93,33%	94,12%	95,50%	95,83%
5 <sup>th</sup> percentile	80,64%	83,82%	79,09%	88,89%	86,39%
● Min	31,58%	66,67%	56,25%	72,22%	80,00%


Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
169	100,00%	169	100,00%

### Comments:

Especially in the lower percentage ranges, this QI of the guideline has improved further, so that for the first time all centres achieved the target. In the previous year, 1 centre had just missed this target. 116 of the 169 centres even achieved a rate of 100%.

\*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators  
 \*\* Percentage of the total number of patients treated in centres according to the indicator.


## 15. Details in the pathology report in the case of initial diagnosis and tumour resection (GL cervix QI)



	Indicator definition	All clinical sites 2020		
		Median	Range	Patients Total
Numerator	Surgical primary cases cervical carcinoma with complete pathology reports (def. see Data Sheet)	7*	0 - 42	1492
Denominator	Surgical primary cases with cervical carcinoma and tumour resection	7*	1 - 45	1597
Rate	Target value ≥ 80%	100%	0,00% - 100%	93,43%**

\*

Sollvorgabe = target value



	2016	2017	2018	2019	2020
● Max	100%	100%	100%	100%	100%
95 <sup>th</sup> percentile	100%	100%	100%	100%	100%
75 <sup>th</sup> percentile	100%	100%	100%	100%	100%
Median	87,23%	87,50%	100%	100%	100%
25 <sup>th</sup> percentile	60,74%	59,73%	66,67%	84,62%	90,36%
5 <sup>th</sup> percentile	12,02%	6,98%	37,50%	71,43%	80,00%
● Min	0,00%	0,00%	0,00%	28,57%	0,00%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
168	99,41%	161	95,83%


### Comments:

This QI of the guideline cervical carcinoma continues to develop very well. The number of centres below the target has further decreased from 12 to 7. The centres concerned mostly referred to individual missing data (3x missing Pn status, 2x missing minimal resection margin), which could only be partially plausibilised. Accordingly, some centres sought discussion with the pathology department in order to be able to submit complete pathology reports of findings in the future.

\*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators  
 \*\* Percentage of the total number of patients treated in centres according to the indicator.




## 16. Details in the pathology report in the case of lymphonodectomy (GL cervix QI)



Sollvorgabe = target value

	Indicator definition	All clinical sites 2020		
		Median	Range	Patients Total
Numerator	Surgical primary cases cervical carcinoma with complete pathology reports (def. see Data Sheet)	5*	1 - 34	1215
Denominator	Surgical cases with cervical carcinoma and lymphonodectomy	5*	1 - 36	1230
Rate	Target value ≥ 80%	100%	80,00% - 100%	98,78%**

\*



	2016	2020	2017	2018	2019	2020
● Max	100%	100%	100%	100%	100%	100%
95 <sup>th</sup> percentile	100%	100%	100%	100%	100%	100%
75 <sup>th</sup> percentile	100%	100%	100%	100%	100%	100%
Median	100%	100%	100%	100%	100%	100%
25 <sup>th</sup> percentile	87,50%	84,62%	95,21%	100%	100%	100%
5 <sup>th</sup> percentile	63,08%	50,00%	63,96%	85,71%	94,20%	94,20%
● Min	21,05%	0,00%	40,00%	71,43%	80,00%	80,00%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
166	98,22%	166	100,00%


### Comments:

This indicator, which is also a QI of the guideline, continues to develop excellently. For the first time, all centres meet the target of at least 80%. The vast majority of centres (155 of 166) had a complete report of findings for all surgical cases with lymphonodectomy.

\*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators  
 \*\* Percentage of the total number of patients treated in centres according to the indicator.




## 17. Cytological/histological lymph node staging (GL cervix QI)



Begründungspflicht = mandatory statement of reasons

	Indicator definition	All clinical sites 2020		
		Median	Range	Patients Total
Numerator	Primary cases with cytological/histological lymph node staging	7*	0 - 42	1495
Denominator	Primary cases with cervical carcinoma FIGO stages ≥ IA2-IVA	10*	1 - 47	1978
Rate	Mandatory statement of reasons*** <0.01%	77,78%	0,00% - 100%	75,58%**



	2016	2017	2018	2019	2020
● Max	100%	100%	100%	100%	100%
95 <sup>th</sup> percentile	100%	100%	100%	100%	100%
75 <sup>th</sup> percentile	88,89%	89,45%	90,91%	85,71%	88,89%
Median	75,00%	80,00%	80,00%	73,51%	77,78%
25 <sup>th</sup> percentile	54,55%	60,77%	66,67%	55,56%	60,00%
5 <sup>th</sup> percentile	17,29%	27,04%	38,50%	25,11%	27,00%
● Min	0,00%	3,85%	0,00%	0,00%	0,00%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
169	100,00%	167	98,82%

### Comments:

The lymph node staging rate has improved significantly. Only 2 centres (previous year: 4) had not performed this in any of the denominator cases. The two centres had 3 and 1 patient in the denominator, respectively, and referred to patients with best supportive care and Hb-effective bleeding, respectively, which was taken as a reason for rapid surgery.


\*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators

\*\* Percentage of the total number of patients treated in centres according to the indicator.


\*\*\* If value is outside the plausibility corridor, centres have to give an explanation.



## 18. Brachytherapy as a component of primary radio(chemo) therapy



	Indicator definition	All clinical sites 2020		
		Median	Range	Patients Total
Numerator	Primary cases of the denominator in which brachytherapy was administered as part of primary radio(chemo) therapy	3*	0 - 33	556
Denominator	Primary cases with cervical carcinoma and primary radio(chemo) therapy	3,5*	1 - 36	704
Rate	Mandatory statement of reasons*** < 75%	89,59%	0,00% - 100%	78,98%**



	2016	2017	2018	2019	2020
● Max	----	----	----	100%	100%
95 <sup>th</sup> percentile	----	----	----	100%	100%
75 <sup>th</sup> percentile	----	----	----	100%	100%
Median	----	----	----	100%	89,59%
25 <sup>th</sup> percentile	----	----	----	66,67%	66,67%
5 <sup>th</sup> percentile	----	----	----	25,00%	0,00%
● Min	----	----	----	0,00%	0,00%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
158	93,49%	106	67,09%

### Comments:


This indicator was collected for the first time on a mandatory basis, which may explain the large differences from the previous year's values. 52 centres had to explain their numbers for brachytherapy as an RCT component. They referred, among other things, to refusal by the patient (11x), technically unfeasible brachytherapy (especially due to stenosis caused by the tumour) (10x), old age or multimorbidity (10x), palliative patients (9x) and contraindications (e.g. vesicovaginal fistula, bleeding tumour, massive previous cardiac disease) (8x). The justifications were plausible in the audits.

\*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators

\*\* Percentage of the total number of patients treated in centres according to the indicator.


\*\*\* If value is outside the plausibility corridor, centres have to give an explanation.

## 19. Details in pathology report in the case of initial diagnosis and tumour resection (GL vulva QI)



Sollvorgabe = target value

	Indicator definition	All clinical sites 2020		
		Median	Range	Patients Total
Numerator	Patients with complete pathology report (def. see Data Sheet)	7*	0 - 44	1340
Denominator	Patients with initial diagnosis vulvar cancer and tumour resection	7*	1 - 45	1418
Rate	Target value ≥80%	100%	0,00% - 100%	94,50%**



	2016	2017	2018	2019	2020
● Max	100%	100%	100%	100%	100%
95 <sup>th</sup> percentile	100%	100%	100%	100%	100%
75 <sup>th</sup> percentile	100%	100%	100%	100%	100%
Median	94,26%	95,22%	100%	100%	100%
25 <sup>th</sup> percentile	79,64%	72,32%	85,71%	88,89%	90,24%
5 <sup>th</sup> percentile	0,00%	18,44%	42,29%	75,00%	75,83%
● Min	0,00%	0,00%	0,00%	0,00%	0,00%


Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
167	98,82%	157	94,01%

**Comments:**


The indicator for the completeness of pathology reports also continues to develop well. 10 centres (previous year: 11) had these in less than 80% of the cases of vulvar carcinoma. Some of the cases could be plausibilised in the audits, e.g. in the case of complete removal of the carcinoma by biopsy (and only VIN III in the preparation) or in the case of rejection of an LNE by the patient. In the other cases, the centres trained the surgeons or consulted with the pathology department.

\*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators  
 \*\* Percentage of the total number of patients treated in centres according to the indicator.

## 20. Details in pathology report in the case of lymphonodectomy (GL vulva QI)



	Indicator definition	All clinical sites 2020		
		Median	Range	Patients Total
Numerator	Primary cases of the denominator with details in the pathology report (def. see Data Sheet)	4*	1 - 35	852
Denominator	Patients with initial diagnosis vulvar cancer and lymphonodectomy	4*	1 - 35	864
Rate	Target value ≥80%	100%	50,00% - 100%	98,61%**



	2016	2020	2017	2018	2019	2020
Max	100%	100%	100%	100%	100%	100%
95 <sup>th</sup> percentile	100%	100%	100%	100%	100%	100%
75 <sup>th</sup> percentile	100%	100%	100%	100%	100%	100%
Median	100%	100%	100%	100%	100%	100%
25 <sup>th</sup> percentile	100%	100%	100%	100%	100%	100%
5 <sup>th</sup> percentile	75,50%	75,33%	83,33%	98,69%	90,91%	
Min	0,00%	0,00%	50,00%	66,67%	50,00%	


Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
161	95,27%	160	99,38%

### Comments:


This QI of the guideline Vulva continues to be implemented excellently by the centres. Once again, one centre failed to meet the target for reports of findings, although this was not the case in the previous year. The centre had only 2 patients in the denominator. In one of the cases, the patient refused the evaluation of the inguinal lymph nodes in advance.

\*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators  
 \*\* Percentage of the total number of patients treated in centres according to the indicator.

## 21. Conduct inguinofemoral staging (GL vulva QI)



	Indicator definition	All clinical sites 2020		
		Median	Range	Patients Total
Numerator	Primary cases of the denominator with surgical staging (systematic lymphonodectomy and sentinel procedures) of inguinofemoral lymph nodes	5*	0 - 24	989
Denominator	Primary cases of vulvar carcinoma ≥ pT1b (without basal cell carcinoma and without verrucous carcinoma)	5*	1 - 25	1093
Rate	Target value ≥ 90%	100%	0,00% - 100%	90,48%**



	2016	2017	2018	2019	2020
● Max	100%	100%	100%	100%	100%
95 <sup>th</sup> percentile	100%	100%	100%	100%	100%
75 <sup>th</sup> percentile	100%	100%	100%	100%	100%
Median	88,89%	93,75%	100%	100%	100%
25 <sup>th</sup> percentile	72,92%	80,00%	80,91%	85,71%	81,82%
5 <sup>th</sup> percentile	50,00%	50,00%	52,14%	50,00%	51,79%
● Min	25,00%	0,00%	0,00%	0,00%	0,00%


Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
166	98,22%	111	66,87%

### Comments:


The fulfilment of this QI of the guideline is approximately at the previous year's level. 46 of the 55 centres that failed to meet the target (8 more than in the previous year) refrained from staging of one or more patients due to old age or comorbidities. 14 centres referred to the patient's wish, 6 each to M1 patients or palliative therapy approaches. This could be explained comprehensibly in the audits. The large scattering of the values is based on the sometimes small numbers of patients in the denominator, due to which even 1 case often led to a shortfall of the target.

\*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators  
 \*\* Percentage of the total number of patients treated in centres according to the indicator.

## 22. Sentinel lymph nodes biopsy (GL vulva QI)



	Indicator definition	All clinical sites 2020		
		Median	Range	Patients Total
Numerator	Primary cases of the denominator with the described. Characteristics with sentinel surgery performed (def. see Data Sheet)	3*	0 - 33	680
Denominator	Primary cases vulvar carcinoma and sentinel lymph node biopsy.	3*	1 - 33	733
Rate	Target value ≥ 80%	100%	0,00% - 100%	92,77%**



	2016	2017	2018	2019	2020
● Max	100%	100%	100%	100%	100%
● 95 <sup>th</sup> percentile	100%	100%	100%	100%	100%
● 75 <sup>th</sup> percentile	100%	100%	100%	100%	100%
● Median	100%	100%	100%	100%	100%
● 25 <sup>th</sup> percentile	55,00%	80,00%	85,71%	100%	98,08%
● 5 <sup>th</sup> percentile	0,00%	8,21%	50,00%	66,67%	63,64%
● Min	0,00%	0,00%	0,00%	0,00%	0,00%


Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
156	92,31%	141	90,38%

### Comments:

The fulfilment of this indicator has slightly decreased. 15 centres (previous year: 11) fulfilled the characteristics of the numerator in less than 80% of cases. The most frequent reason (4 mentions) was tumours that subsequently turned out to be > 4 cm. All other reasons (e.g. prognosis-determining second malignancy) were mentioned only sporadically. The centres reacted with training or sensitisation of their staff.


\*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators  
 \*\* Percentage of the total number of patients treated in centres according to the indicator.

## 23. Systematic lymphadenectomy (LNE) for type-I-endometrial carcinoma (GL Endo QI)



	Indicator definition	All clinical sites 2020		
		Median	Range	Patients Total
Numerator	Primary cases of the denominator with systematic lymphadenectomy	0*	0 - 9	32
Denominator	Primary cases type I endometrial carcinoma (ICD-0: 8380/3, 8570/3, 8263/3, 8382/3, 8480/3) pT1a, G1/2, cN0	9*	1 - 44	1527
Rate	Target value ≤ 5%	0,00%	0,00% - 100%	2,10%**

Sollvorgabe = target value



	2016	2017	2018	2019	2020
Max	-----	-----	33,33%	33,33%	100%
95 <sup>th</sup> percentile	-----	-----	14,11%	9,09%	13,81%
75 <sup>th</sup> percentile	-----	-----	0,00%	0,00%	0,00%
Median	-----	-----	0,00%	0,00%	0,00%
25 <sup>th</sup> percentile	-----	-----	0,00%	0,00%	0,00%
5 <sup>th</sup> percentile	-----	-----	0,00%	0,00%	0,00%
Min	-----	-----	0,00%	0,00%	0,00%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
164	97,04%	146	89,02%


**Comments:**

This QI of the guideline is fully implemented by the vast majority of centres (144) (rate 0%). However, with 18 centres, more fail to meet the target than in the previous year (16). In most cases, the curettage material was initially classified as G3 (and later downgraded, 5 mentions) or the pre- or intraoperative assessment of a tumour > pT1a was revised (4x). The centres partly used the results as an occasion for critical internal discussions, for example on the significance of imaging vs. pathological staging. The centre with a rate of 100% had only 1 patient in the denominator.


\*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators  
 \*\* Percentage of the total number of patients treated in centres according to the indicator.



## 24. Adjuvant chemotherapy for type-I-endometrial carcinoma (GL Endo QI)



	Indicator definition	All clinical sites 2020		
		Median	Range	Patients Total
Numerator	No Adjuvant chemotherapy for type-I-endometrial carcinoma pT1a/b G1 cN0/pN0 o. pT1a/b G2 cN0/pN0	0*	0 - 3	11
Denominator	Primary cases of the denominator with adjuvant chemotherapy	11*	1 - 54	2110
Rate	Target value ≤ 5%	0,00%	0,00% - 28,57%	0,52%**



	2016	2017	2018	2019	2020
Max	-----	-----	20,00%	25,00%	28,57%
95 <sup>th</sup> percentile	-----	-----	4,76%	4,57%	0,00%
75 <sup>th</sup> percentile	-----	-----	0,00%	0,00%	0,00%
Median	-----	-----	0,00%	0,00%	0,00%
25 <sup>th</sup> percentile	-----	-----	0,00%	0,00%	0,00%
5 <sup>th</sup> percentile	-----	-----	0,00%	0,00%	0,00%
Min	-----	-----	0,00%	0,00%	0,00%

Clinical sites with evaluable data		Clinical sites within the plausibility limits	
Number	%	Number	%
167	98,82%	161	96,41%

**Comments:**

159 centres have fully implemented this QI of the guideline (rate 0%). With a slightly lower overall rate, 1 centre more than in the previous year failed to meet the target of a maximum of 5%. The decisive cases were plausible individual decisions, such as treatment within the framework of a study, in the case of concurrent ovarian carcinoma or in the case of an M1 patient.

\*The medians for numerator and population do not refer to an existing Centre but indicate the median of all cohort numerators and the median of all cohort denominators

\*\* Percentage of the total number of patients treated in centres according to the indicator.

\*\*\* If value is outside the plausibility corridor, centres have to give an explanation.



# WISSEN AUS ERSTER HAND (FIRST-HAND KNOWLEDGE)



Find out more on [www.krebsgesellschaft.de](http://www.krebsgesellschaft.de)

## Autoren

Deutsche Krebsgesellschaft e.V.  
Deutsche Gesellschaft für Gynäkologie u. Geburtshilfe e.V.  
Arbeitsgemeinschaft Gynäkologische Onkologie e.V.  
Zertifizierungskommission Gynäkologische Krebszentren  
Mathias W. Beckmann, Sprecher Zertifizierungskommission  
Christian Dannecker, Stellv. Sprecher Zertifizierungskommission  
Simone Wesselmann, Deutsche Krebsgesellschaft e.V.  
Johannes Rückher, Deutsche Krebsgesellschaft e.V.  
Martin Utzig, Deutsche Krebsgesellschaft e.V.  
Ellen Griesshammer, Deutsche Krebsgesellschaft e.V.  
Agnes Bischofberger, OnkoZert  
Florina Dudu, OnkoZert

## Imprint

Publisher and responsible for content:  
Deutsche Krebsgesellschaft (DKG)  
Kuno-Fischer-Straße 8  
14057 Berlin  
Tel.: +49 (030) 322 93 29 0  
Vereinsregister Amtsgericht Charlottenburg,  
Vereinsregister-Nr.: VR 27661 B  
V.i.S.d.P.: Dr. Johannes Bruns

in cooperation with:  
OnkoZert, Neu-Ulm  
[www.onkozert.de](http://www.onkozert.de)

Version e-A1-en; Stand 11.07.2022

ISBN: 978-3-910336-04-9

